ES2405531R1 - Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal - Google Patents

Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal

Info

Publication number
ES2405531R1
ES2405531R1 ES201131774A ES201131774A ES2405531R1 ES 2405531 R1 ES2405531 R1 ES 2405531R1 ES 201131774 A ES201131774 A ES 201131774A ES 201131774 A ES201131774 A ES 201131774A ES 2405531 R1 ES2405531 R1 ES 2405531R1
Authority
ES
Spain
Prior art keywords
solid
maintenance
solid formulations
gastrointestinal health
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201131774A
Other languages
English (en)
Other versions
ES2405531A2 (es
ES2405531B1 (es
Inventor
Peter Stein
Ian Cox
Samuel Smith
Leighton Jones
Joerg Plessl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norgine BV
Original Assignee
Norgine BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1018647.6A external-priority patent/GB201018647D0/en
Priority claimed from GBGB1104049.0A external-priority patent/GB201104049D0/en
Priority claimed from GBGB1107626.2A external-priority patent/GB201107626D0/en
Application filed by Norgine BV filed Critical Norgine BV
Publication of ES2405531A2 publication Critical patent/ES2405531A2/es
Publication of ES2405531R1 publication Critical patent/ES2405531R1/es
Application granted granted Critical
Publication of ES2405531B1 publication Critical patent/ES2405531B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal. La presente invención se relaciona con una formulación sólida para administración oral como un sólido que comprende polietilenglicol y un sólido adicional tal como manitol. La formulación puede usarse para prevenir trastornos gastrointestinales tales como constipación de vientre en sujetos sanos. En algunas realizaciones, la formulación sólida es para masticar o para chupar.
ES201131774A 2010-11-04 2011-11-04 Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal Active ES2405531B1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB1018647.6A GB201018647D0 (en) 2010-11-04 2010-11-04 Formulations
GB1018647 2010-11-04
US41210910P 2010-11-10 2010-11-10
US61/412109 2010-11-10
GBGB1104049.0A GB201104049D0 (en) 2011-03-09 2011-03-09 Formulations
GB1104049 2011-03-09
GBGB1107626.2A GB201107626D0 (en) 2011-05-06 2011-05-06 Formulations
GB1107626 2011-05-06

Publications (3)

Publication Number Publication Date
ES2405531A2 ES2405531A2 (es) 2013-05-31
ES2405531R1 true ES2405531R1 (es) 2013-06-07
ES2405531B1 ES2405531B1 (es) 2014-06-11

Family

ID=44999794

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201131774A Active ES2405531B1 (es) 2010-11-04 2011-11-04 Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal

Country Status (20)

Country Link
US (3) US20130225692A1 (es)
EP (1) EP2635264B8 (es)
JP (1) JP5872573B2 (es)
KR (1) KR20130101102A (es)
CN (1) CN103384516B (es)
AR (1) AR083769A1 (es)
AU (1) AU2011324995B2 (es)
BE (1) BE1019493A3 (es)
BR (1) BR112013010884A2 (es)
CA (1) CA2816835A1 (es)
EA (1) EA024566B1 (es)
ES (1) ES2405531B1 (es)
IL (1) IL225892A0 (es)
MX (1) MX342181B (es)
MY (1) MY164204A (es)
NL (1) NL2007716C2 (es)
NZ (1) NZ611148A (es)
SG (1) SG190018A1 (es)
TW (1) TWI520730B (es)
WO (1) WO2012059724A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
US20130209522A1 (en) * 2012-02-06 2013-08-15 University Of Utah Research Foundation Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft
WO2014040994A1 (en) 2012-09-11 2014-03-20 Norgine Bv Compositions comprising peg and ascorbate
US9889235B2 (en) 2013-02-05 2018-02-13 University Of Utah Research Foundation Implantable devices for bone or joint defects
EP3563838A1 (en) 2013-03-15 2019-11-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of suflate salts and methods of use thereof
JP2017514521A (ja) 2014-04-29 2017-06-08 コロナリーコンセプツ エルエルシー 電解質補給物をもたらすための食品、システム、方法、及びキット
KR20180041230A (ko) * 2015-09-01 2018-04-23 코로나리콘셉츠 엘엘씨 완하제 제제 및 제조
EP3473183A4 (en) 2016-06-15 2020-02-12 Shimadzu Corporation RADIATION IMAGING DEVICE
FR3056109B1 (fr) * 2016-09-21 2019-10-11 Pierre Fabre Medicament Utilisation de formulations solides de polyethylene glycol dans le traitement de la constipation
CN112386577B (zh) * 2019-08-16 2024-01-23 北京天衡药物研究院有限公司 一种治疗便秘的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003685A1 (en) * 1995-07-14 1997-02-06 Halow George M Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
WO2005102364A1 (en) * 2004-04-23 2005-11-03 Norgine Europe Bv Compressed pharmaceutical compositions comprising peg and electrolytes
WO2006122104A1 (en) * 2005-05-06 2006-11-16 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516291C (en) * 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003685A1 (en) * 1995-07-14 1997-02-06 Halow George M Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
WO2005102364A1 (en) * 2004-04-23 2005-11-03 Norgine Europe Bv Compressed pharmaceutical compositions comprising peg and electrolytes
WO2006122104A1 (en) * 2005-05-06 2006-11-16 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition

Also Published As

Publication number Publication date
EP2635264A1 (en) 2013-09-11
EA024566B1 (ru) 2016-09-30
MY164204A (en) 2017-11-30
MX2013004972A (es) 2013-08-27
WO2012059724A8 (en) 2013-06-06
AR083769A1 (es) 2013-03-20
MX342181B (es) 2016-09-20
CN103384516B (zh) 2017-02-15
JP5872573B2 (ja) 2016-03-01
US20160193245A1 (en) 2016-07-07
NL2007716A (en) 2012-05-07
US20170296575A1 (en) 2017-10-19
SG190018A1 (en) 2013-06-28
AU2011324995A1 (en) 2013-05-02
NZ611148A (en) 2015-09-25
ES2405531A2 (es) 2013-05-31
BE1019493A3 (fr) 2012-07-03
US20130225692A1 (en) 2013-08-29
EP2635264B8 (en) 2018-07-18
ES2405531B1 (es) 2014-06-11
JP2014500246A (ja) 2014-01-09
CA2816835A1 (en) 2012-05-10
CN103384516A (zh) 2013-11-06
TW201223522A (en) 2012-06-16
KR20130101102A (ko) 2013-09-12
AU2011324995B2 (en) 2015-12-24
EP2635264B1 (en) 2018-05-30
TWI520730B (zh) 2016-02-11
EA201300539A1 (ru) 2013-09-30
IL225892A0 (en) 2013-06-27
BR112013010884A2 (pt) 2016-08-02
NL2007716C2 (en) 2012-11-13
WO2012059724A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
ES2405531R1 (es) Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
WO2015160842A8 (en) Methods and formulations of capsaicinoids and capsinoids
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
ZA201206360B (en) Solid composition for the oral administration of dyes and diagnostic use thereof
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
MY161595A (en) Oral care compositions
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
WO2011146876A3 (en) Oral transmucosal administration of sufentanil
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112012019997A2 (pt) composições de cuidado oral
BRPI1006040A2 (pt) uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
TN2015000135A1 (en) Modified release formulations for oprozomib
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX345888B (es) Emulsion aceite en agua de mometasona y propilenglicol.
CO6602160A2 (es) Terapia de b12 oral
TN2013000172A1 (en) Formulations comprising polyethylene glycol
PE20150865A1 (es) Composiciones liquidas orales pediatricas que contienen nepadutant
MX357329B (es) Extracto crudo de un hibrido de sechium edule, metodo para su extraccion y su uso para formulaciones con efecto antineoplasico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2405531

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140611